RETRACTED: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).This article has been retracted at the request of the Editor.The authors have published results from exactly the same clinical study and patient population in 6 separate articles, without referencing the publications in any of the later articles:1Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'angelo, A., Maffioli, P.Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.Clinical and Experimental Hypertension 2013 (35) 301–307DOI: 10.3109/10641963.2012.7218412Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P.Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies.Journal of Clinical Pharmacy and Therapeutics 2013 (38) 48–55DOI: 10.1111/jcpt.120213Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P.Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.Journal of the American Society of Hypertension 2013 (7) 32–39DOI: 10.1016/j.jash.2012.11.0064Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P.Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.Expert Opinion on Drug Safety 2013 (12) 621–629DOI: 10.1517/14740338.2013.8166745Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P.Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.Inflammation 37 (2014) 154–162DOI: 10.1007/s10753-013-9724-x6Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., Maffioli, P.Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.European Journal of Pharmaceutical Sciences, 2014 (51) 26–33DOI: 10.1016/j.ejps.2013.08.031In addition, the article in the European Journal of Pharmaceutical Sciences contains results previously published in articles 1, 2 and 5, which is the main reason for retraction of the article in the European Journal of Pharmaceutical Sciences.